{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:29Z","timestamp":1790679209326,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kurt+Peter Foundation"},{"DOI":"10.13039\/100013780","name":"LGMD2I Research Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Samantha J Brazzo Foundation"},{"name":"LGMD2D Foundation"},{"DOI":"10.13039\/501100008164","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008164","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Coalition to Cure Calpain 3"},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["UM1 HG008900"],"award-info":[{"award-number":["UM1 HG008900"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["UM1 HG008900"],"award-info":[{"award-number":["UM1 HG008900"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UM1 HG008900"],"award-info":[{"award-number":["UM1 HG008900"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UM1 HG008900"],"award-info":[{"award-number":["UM1 HG008900"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["UM1 HG008900"],"award-info":[{"award-number":["UM1 HG008900"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["UM1 HG008900"],"award-info":[{"award-number":["UM1 HG008900"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MDA\/AANEM Development Grant"},{"name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","award":["175083"],"award-info":[{"award-number":["175083"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0722-1","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T12:09:19Z","timestamp":1510920559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness"],"prefix":"10.1186","volume":"12","author":[{"given":"Katherine","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"T\u00f6pf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidosava Rakocevic","family":"Stojanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stojan","family":"Peri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maddison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ela","family":"Akay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0141usakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monkol","family":"Lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"MacArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"722_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671\u20136.","journal-title":"J Pediatr"},{"key":"722_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.c.31322","volume":"160C","author":"A Schuller","year":"2012","unstructured":"Schuller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160C:80\u20138.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"722_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8:267\u201388.","journal-title":"Genet Med"},{"key":"722_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","volume":"79","author":"F Martiniuk","year":"1998","unstructured":"Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79:69\u201372.","journal-title":"Am J Med Genet"},{"key":"722_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","volume":"7","author":"MG Ausems","year":"1999","unstructured":"Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7:713\u20136.","journal-title":"Eur J Hum Genet"},{"key":"722_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/humu.22108","volume":"33","author":"M Kroos","year":"2012","unstructured":"Kroos M, Hoogeveen-Westerveld M, Michelakakis H, et al. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Hum Mutat. 2012;33:1161\u20135.","journal-title":"Hum Mutat"},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/01.gim.0000217789.14470.c5","volume":"8","author":"LE Case","year":"2006","unstructured":"Case LE, Kishnani PS. Physical therapy management of Pompe disease. Genet Med. 2006;8:318\u201327.","journal-title":"Genet Med"},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66:329\u201335.","journal-title":"Pediatr Res"},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1468-1331.2008.02377.x","volume":"16","author":"T Merk","year":"2009","unstructured":"Merk T, Wibmer T, Schumann C, Kruger S. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults. Eur J Neurol. 2009;16:274\u20137.","journal-title":"Eur J Neurol"},{"key":"722_CR10","doi-asserted-by":"publisher","first-page":"e1327","DOI":"10.1542\/peds.2007-0388","volume":"120","author":"AR Kemper","year":"2007","unstructured":"Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics. 2007;120:e1327\u201334.","journal-title":"Pediatrics"},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrg3031","volume":"12","author":"MJ Bamshad","year":"2011","unstructured":"Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12:745\u201355.","journal-title":"Nat Rev Genet"},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nrneurol.2016.35","volume":"12","author":"R Thompson","year":"2016","unstructured":"Thompson R, Straub V. Limb-girdle muscular dystrophies - international collaborations for translational research. Nat Rev Neurol. 2016;12:294\u2013309.","journal-title":"Nat Rev Neurol"},{"key":"722_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/humu.22347","volume":"34","author":"M Girdea","year":"2013","unstructured":"Girdea M, Dumitriu S, Fiume M, et al. PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat. 2013;34:1057\u201365.","journal-title":"Hum Mutat"},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285\u201391.","journal-title":"Nature"},{"key":"722_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297\u2013303.","journal-title":"Genome Res"},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491\u20138.","journal-title":"Nat Genet"},{"key":"722_CR17","doi-asserted-by":"crossref","unstructured":"Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics 2013; 43: 11. 10:11\u201333.","DOI":"10.1002\/0471250953.bi1110s43"},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248\u20139.","journal-title":"Nat Methods"},{"key":"722_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073\u201381.","journal-title":"Nat Protoc"},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth.2890","volume":"11","author":"JM Schwarz","year":"2014","unstructured":"Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11:361\u20132.","journal-title":"Nat Methods"},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/humu.22225","volume":"34","author":"HA Shihab","year":"2013","unstructured":"Shihab HA, Gough J, Cooper DN, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat. 2013;34:57\u201365.","journal-title":"Hum Mutat"},{"key":"722_CR22","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980\u20135.","journal-title":"Nucleic Acids Res"},{"key":"722_CR23","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/hmg\/3.7.1081","volume":"3","author":"ML Huie","year":"1994","unstructured":"Huie ML, Chen AS, Tsujino S, et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (\u221213T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet. 1994;3:2231\u20136.","journal-title":"Hum Mol Genet"},{"key":"722_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ymgme.2007.05.011","volume":"92","author":"L Gort","year":"2007","unstructured":"Gort L, Coll MJ, Chabas A. Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation. Mol Genet Metab. 2007;92:183\u20137.","journal-title":"Mol Genet Metab"},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1136\/jmedgenet-2011-100223","volume":"48","author":"J Majewski","year":"2011","unstructured":"Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can exome sequencing do for you? J Med Genet. 2011;48:580\u20139.","journal-title":"J Med Genet"},{"key":"722_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13023-016-0390-6","volume":"11","author":"S Levesque","year":"2016","unstructured":"Levesque S, Auray-Blais C, Gravel E, et al. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. Orphanet J Rare Dis. 2016;11:8.","journal-title":"Orphanet J Rare Dis"},{"key":"722_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ncl.2014.04.005","volume":"32","author":"MP Wicklund","year":"2014","unstructured":"Wicklund MP, Kissel JT. The limb-girdle muscular dystrophies. Neurol Clin. 2014;32:729\u201349. ix","journal-title":"Neurol Clin"},{"key":"722_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.0000000000002800","volume":"87","author":"M Savarese","year":"2016","unstructured":"Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. Neurology. 2016;87:71\u20136.","journal-title":"Neurology"},{"key":"722_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","volume":"54","author":"YH Chien","year":"2013","unstructured":"Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013;54:219\u201327.","journal-title":"Pediatr Neonatol"},{"key":"722_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/2013.jamaneurol.486","volume":"70","author":"J Vissing","year":"2013","unstructured":"Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. JAMA Neurol. 2013;70:923\u20137.","journal-title":"JAMA Neurol"},{"key":"722_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1212\/WNL.0000000000002758","volume":"87","author":"Z Lukacs","year":"2016","unstructured":"Lukacs Z, Nieves Cobos P, Wenninger S, et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology. 2016;87:295\u20138.","journal-title":"Neurology"},{"key":"722_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12881-014-0141-2","volume":"15","author":"X Liu","year":"2014","unstructured":"Liu X, Wang Z, Jin W, et al. Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation. BMC Med Genet. 2014;15:141.","journal-title":"BMC Med Genet"},{"key":"722_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/humu.20374","volume":"27","author":"AL Montalvo","year":"2006","unstructured":"Montalvo AL, Bembi B, Donnarumma M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27:999\u20131006.","journal-title":"Hum Mutat"},{"key":"722_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1212\/WNL.55.8.1122","volume":"55","author":"P Laforet","year":"2000","unstructured":"Laforet P, Nicolino M, Eymard PB, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000;55:1122\u20138.","journal-title":"Neurology"},{"key":"722_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","volume":"25","author":"O Musumeci","year":"2015","unstructured":"Musumeci O, Thieme A, Claeys KG, et al. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum. Neuromuscul Disord. 2015;25:719\u201324.","journal-title":"Neuromuscul Disord"},{"key":"722_CR36","unstructured":"Leslie N, Tinkle BT: Glycogen storage disease type II (Pompe disease); in: Pagon RA, Adam MP, Ardinger HH et al. (eds): GeneReviews(R). Seattle (WA), 2007."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-017-0722-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T10:29:09Z","timestamp":1589538549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0722-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]},"assertion":[{"value":"12 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Full ethics approval was granted for the Newcastle MRC Centre Biobank for Rare and Neuromuscular Diseases by the Newcastle and North Tyneside research ethics committee (REC reference number 09\/H0906\/28). All patients provided informed consent for the storage and use of their biomaterial in the Newcastle MRC Centre Biobank for Rare and Neuromuscular Diseases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VS is or has been a principal investigator for trials sponsored by Sanofi Genzyme, GSK, Prosensa\/BioMarin Pharmaceuticals, Ionis Pharmceuticals and Sarepta Therapeutics. VS received speaker honoraria from Sanofi Genzyme. For the last 3\u00a0years VS is or has been on advisory boards for Audentes Therapeutics, Biogen, Bristol-Myer Squibb, Italfarmaco S.p.A., Sarepta Therapeutics, Summit Therapeutics, Tivorsan Pharmaceuticals, TrophyNOD, and Wave Therapeutics. KGC is principal investigator for trials sponsored by Sanofi Genzyme and KGC received speaker honoraria and travel grants from Sanofi Genzyme. The authors\u2019 declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"173"}}